EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSNBRG00000023895
Gene Symbol: PTAFR
1 Cross references
211 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSNBRG00000023904
Gene Symbol: PTAFR
1 Cross references
208 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSNBRG00000018273
Gene Symbol: LOC102800283
3 Cross references
203 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Alpha-Like

Ensembl ID : ENSNBRG00000003739
Gene Symbol: LOC102779838
3 Cross references
203 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSNBRG00000010129
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSNBRG00000006324
Gene Symbol: PLK1
2 Cross references
188 Possible Orthologues:

Poly [Adp-Ribose] Polymerase 1-Like

Ensembl ID : ENSNBRG00000017434
Gene Symbol: LOC102777090
3 Cross references
209 Possible Orthologues:

Poly [Adp-Ribose] Polymerase 2-Like

Ensembl ID : ENSNBRG00000015824
Gene Symbol: LOC102793357
3 Cross references
185 Possible Orthologues:

Poly [Adp-Ribose] Polymerase 3-Like

Ensembl ID : ENSNBRG00000004669
Gene Symbol: LOC102797313
3 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSNBRG00000021619
Gene Symbol: PORCN
3 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSNBRG00000018426
Gene Symbol: KCNMA1
3 Cross references
235 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSNBRG00000015277
Gene Symbol: KCNMA1
4 Cross references
239 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).